Search | Clinical Trials Finder

Conditions: Brain Neoplasms
Interventions: Nivolumab, Temozolomide, Radiotherapy, Nivolumab Placebo; Drug · Radiation · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Melanoma
Interventions: AZD6244, Dacarbazine, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 2
States / cities: Aurora, Colorado • Boston, Massachusetts

Conditions: Melanoma
Interventions: Intetumumab, Dacarbazine, Placebo; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 17
States / cities: Scottsdale, Arizona • La Jolla, California • Santa Monica, California + 14 more

Conditions: Glioblastoma
Interventions: Pembrolizumab, HSPPC-96, Temozolomide, Placebo, Surgery; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors
Interventions: dasatinib, temozolomide, placebo, radiation therapy; Drug · Other · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 207
States / cities: Hartford, Connecticut • Jacksonville, Florida • Columbus, Georgia + 135 more

Conditions: Cancer, Melanoma
Interventions: Sorafenib (Nexavar, BAY43-9006), Placebo, Dacarbazine; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 14
States / cities: Tucson, Arizona • Aurora, Colorado • Lakeland, Florida + 9 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Quality-of-Life Assessment, Temozolomide, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 390
States / cities: Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 287 more

Conditions: Metastatic Breast Cancer
Interventions: Placebo, Veliparib, Carboplatin, Temozolomide, Paclitaxel; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 34
States / cities: Birmingham, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 24 more

Conditions: Glioblastoma Multiforme
Interventions: Lucanthone, Temozolomide (TMZ), Radiation, Placebo; Drug · Radiation
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 6
States / cities: La Jolla, California • Orange, California • Amherst, New York + 2 more

Conditions: Leiomyosarcoma
Interventions: Unesbulin, Dacarbazine, Placebo; Drug · Other
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 359 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Duarte, California • Los Angeles, California • Santa Monica, California + 18 more

Conditions: Recurrent Lung Small Cell Carcinoma
Interventions: Laboratory Biomarker Analysis, Placebo Administration, Temozolomide, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2027
U.S. locations: 14
States / cities: Tampa, Florida • Atlanta, Georgia • Baltimore, Maryland + 10 more

Conditions: Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide; Radiation · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more

Conditions: Melanoma
Interventions: dacarbazine plus Genasense, dacarbazine plus placebo; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 14
States / cities: Mobile, Alabama • Encinitas, California • Santa Rosa, California + 11 more

Conditions: Astrocytoma, IDH-Mutant, Grade 3
Interventions: Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning, Intensity-Modulated Proton Therapy, Temozolomide, Vorasidenib, Placebo Administration, Biospecimen Collection, Magnetic Resonance Imaging, Questionnaire Administration; Radiation · Procedure · Drug + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 12 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2040
U.S. locations: 121
States / cities: Bakersfield, California • Duarte, California • Irvine, California + 96 more

Conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
Interventions: Cannabidiol, Bortezomib, Leucovorin, 5-FU, Oxaliplatin, Bevacizumab, Irinotecan, Gemcitabine, Temozolomide; Drug
Lead sponsor: Leaf Vertical Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Glioma
Interventions: rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adult Glioblastoma, Adult Gliosarcoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Cediranib Maleate, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo Administration, Temozolomide; Radiation · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 105
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 84 more

Conditions: Brain and Central Nervous System Tumors
Interventions: prinomastat, temozolomide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glioblastoma
Interventions: Enzastaurin Hydrochloride, Placebo, Temozolomide, Radiotherapy; Drug · Other · Radiation
Lead sponsor: Denovo Biopharma LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Malignant Neoplasms of Brain
Interventions: PEP-3-KLH conjugate vaccine, daclizumab, temozolomide, placebo, PEP-3-KLH; Biological · Drug · Other
Lead sponsor: John Sampson; Other
Eligibility: 18 Years to 120 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Glioblastoma
Interventions: Bevacizumab, Temozolomide, Radiation therapy, Placebo; Drug · Radiation
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 921 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 6 more

Conditions: Melanoma
Interventions: Ipilimumab, Placebo, Dacarbazine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 681 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 32
States / cities: Anaheim, California • La Verne, California • Los Angeles, California + 28 more

Conditions: Glioblastoma
Interventions: Optune® device, Temozolomide, Pembrolizumab, Placebo; Device · Drug
Lead sponsor: NovoCure GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 741 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 36
States / cities: Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 31 more

Conditions: Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma, Soft-Tissue Sarcoma
Interventions: AL3818, Dacarbazine, AL3818 or placebo, Midazolam 2 mg for CYP3A4 phenotyping, Digoxin (0.25mg), Rosuvastatin 10 mg tablet.; Drug
Lead sponsor: Advenchen Laboratories, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 14 more

Search by objective public record fields.

An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Dasatinib or Placebo, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)

A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery

A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)